RAD51D

MyRisk®, FirstGene®, Prequel®, and Foresight® studies among 10 datasets to be shared by MyriadSALT LAKE CITY, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will showcase 10 studies highlighting its advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 43rd Annual Conference, which will take place from Sept. 17-21, 2024, in New Orleans, LA. The research will highlight the value of genetic and genomic testing in patient care and will cover the company’s MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen and Foresight Carrier Screen. “At Myriad, we’re committed to partnering with genetic counselors in an effort to make genetic testing more accessible, affordable and easier to use for all patient populations,” said Susan Manley, Senior Vice President of Medical Services, Myriad Genetics. “We’re excited to share our new research with the genetic counselor community at this year’s NSGC Conference and to showcase how our latest advancements may help better inform personalized care and improve outcomes for patients.” Myriad’s latest innovations and support services will be on display at booth #119 and through a series of poster presentations at the conference. Myriad’s Presentation Schedule Wednesday, Sept. 18, 2024, from 12:15-2:00pm and 5:45-7:00pm CDT Poster CAN91: Age at Diagnosis of Breast Cancer for Women with Pathogenic Variants in BARD1, RAD51C, and RAD51DSummary: This study shows that the median age of breast cancer diagnosis with pathogenic variants (PVs) in BARD1, RAD51C, and RAD51D is similar to that of other breast cancer genes. Additionally, it shows that a significant number of PV carriers are diagnosed prior to the recommended screening age of 40 years. Poster PRE323: Outcomes in pregnancies that screened positive for rare autosomal aneuploidies (RAAs) Summary: By linking prenatal cell-free DNA results to insurance claims data, this study provides evidence that RAA-screen positive patients have higher rates of miscarriage and preterm birth as compared to RAA-screen negative patients. Poster PRE333: Complications and outcomes of pregnancies screening positive for microdeletions 22q11.2, 15q11.2, 1p36, 4p, or 5pSummary: This study shows that microdeletion screen-positive pregnancies may experience higher rates of ultrasound abnormalities and pregnancy complications. Poster PRE347: Validation of fetal and maternal recessive disease genotyping with FirstGene: a combined, non-invasive prenatal cfDNA assay for fetal aneuploidy, recessive diseases, and serological screeningSummary: This study indicates that the FirstGene screen accurately identifies fetal SNV and INDELs for recessive conditions. Poster PRE349: Validation of fetal and maternal spinal muscular atrophy (SMA) and hemoglobin (Hb) Bart’s screening with FirstGene, a combined, non-invasive prenatal cfDNA assay for fetal aneuploidy, recessive diseases, and serological screening Summary: This study indicates that the FirstGene screen accurately identifies maternal and fetal SMA and Hb Bart’s disease status. Poster PRE351: Validation of fetal RHD copy number calling in FirstGene, a combined, non-invasive prenatal cfDNA assay for fetal aneuploidy, recessive diseases, and serological screeningSummary: This study indicates that the FirstGene assay accurately determines fetal RHD copy number in RhD-negative pregnant patients. Thursday, Sept. 19, 2024, from 12:00-3:00pm and 4:30-6:30pm CDT Poster PRE324: A comparison of carrier rates derived from different data sourcesSummary: This study shows high concordance in carrier rates between Myriad’s database and gnomAD data. Poster PRE344: Investigating cancer diagnosis codes after atypical findings on noninvasive prenatal cell-free DNA (pcfDNA) screeningSummary: This study indicates that patients with an autosomal monosomy or multiple aneuploidies on pcfDNA have a higher risk of a cancer diagnosis than those without. Poster PRE348: Validation of fetal aneuploidy detection with FirstGene: a combined, non-invasive prenatal cfDNA assay for fetal aneuploidy, recessive diseases, and serological screeningSummary: This study indicates that fetal aneuploidy screening on the FirstGene assay is comparable to that of standalone WGS-based pcfDNA screening with fetal fraction amplification. Lunch Symposium: At 12:45pm CDT, Myriad will host a lunch symposium titled ‘How genetic counselors can integrate breast cancer risk assessment programs into surgical, primary care, OB/GYN, and imaging clinics’, moderated by Myriad’s Susan Manley. Myriad will also have a virtual presentation, Characteristics and Cancer Incidence in MITF p.E318K Carriers, available for viewing on the NSGC online experience platform. This study shows that MITF carriers have an increased risk of melanoma, but not renal cancer, as several other studies have suggested. For more information about Myriad’s presence at NSGC, please visit: https://myriad.com/nsgc2024/. Updates will also be shared across Myriad’s LinkedIn and X channels throughout the conference. About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com. Safe Harbor StatementThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's commitment to partnering with genetic counselors in an effort to make genetic testing more accessible, affordable and easier to use for all patient populations and how the company’s latest advancement may help better inform personalized care and improve outcomes for patients. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. Investor ContactMatt Scalo(801) 584-3532IR@myriad.com Media ContactGlenn Farrell(385) 318-3718PR@myriad.com

Integrated Approach Expected to Improve Early Detection Threefold in High-Risk Women; Five-Year Survival Rate Increases to 99% With Early-Stage Diagnosis LOS GATOS, Calif. and RICHARDSON, Texas, Nov. 28, 2022 /PRNewswire/ -- HALO Diagnostics, the leader in early disease detection using precision diagnostics, and Ikonopedia, a next-generation breast imaging reporting and tracking solution, today announced a genetic testing partnership to improve breast cancer detection and patient outcomes. Genetic testing is the most effective way to determine if a patient has specific pathogenic mutations linked to a higher risk for developing cancer, yet only one in five women appropriate for hereditary cancer testing are offered the option.1 Without integrated genetic testing and supplemental breast MRI, traditional imaging centers miss two out of three cancers in high-risk women.2 HALO and Ikonopedia use genetic testing to catch cancers early and increase adherence to critical follow-up imaging. Under the new partnership, Ikonopedia's cutting-edge mammography software for follow up tracking and one-click radiology reporting will be seamlessly integrated with HALO's proprietary genetic lab and precision diagnostic software services. This integrated approach is expected to drive a 40% increase in compliance for follow-up imaging,3 aiding early detection and less invasive treatment. Nearly all patients (97%) with positive genetic test results comply with additional screening recommendations.3 There is a threefold increased cancer detection rate with supplemental breast MRI screening in high-risk women.4 Over 99% of patients survive more than five years with an early-stage breast cancer diagnosis.5 The joint offering aims to maximize identification of patient risk by using Tyrer-Cuzick 8, HALO's Hereditary Gene Panel, and HALO's Polygenic Risk Score. The partnership provides radiology centers: HALO's proprietary genetic lab and precision diagnostic software services with integrated genetic counseling, and a dedicated lab liaison who will work onsite at the radiology center. Seamless intake integration, auto eligibility checks, auto lab ordering, and lab processing. Comprehensive precision diagnostic report including recommended follow-up imaging for patients identified as high risk for breast cancer. "We're proud to partner with Ikonopedia and their robust breast imaging reporting and risk-assessment tools," said Brian Axe, Founder and Chief Product Officer of HALO. "Our combined solution will save lives by improving early detection through fast, accurate diagnosis and personalized care." As part of the collaboration, Ikonopedia's integrated risk assessment tool will identify patients eligible for hereditary testing. When medically indicated, physicians will place an order for HALO's proprietary Women's Health Precision Diagnostic suite, which combines advanced imaging, a risk calculator, and genetic test results to identify patients who may benefit from additional supplemental breast cancer screening and management. "HALO and Ikonopedia's goals for early detection and personalized treatment are incredibly well aligned. We're excited to partner with a forward-thinking, precision diagnostics company to enable broader access to genetic testing and improved follow up," said Emily Crane, CEO & President of Ikonopedia. About HALO Diagnostics HALO Diagnostics is the leader in early disease detection using precision diagnostics. The company's outpatient Precision Diagnostic Centers are reshaping the healthcare ecosystem by integrating advanced imaging, digital pathology, molecular genomics, and predictive analytics under one roof, in a lower-cost, outpatient setting. HALO makes early-stage disease screening and diagnosis faster and more convenient for patients and physicians alike. With care pathways dedicated to prostate cancer, breast cancer, cardiac disease, lung disease, and dementia, HALO is increasing early disease detection and saving lives. HALO currently serves one million patients, a number expected to triple by 2024. For more information visit . About Ikonopedia Ikonopedia was founded by three expert breast imaging Radiologists: László Tabár, MD is the author of 6 books in 10 languages on mammography and a world-renowned educator; A. Thomas Stavros, MD is the author of one of the most popular reference books in the field of breast ultrasound; and Michael J. Vendrell, MD is an expert in breast MRI and CAD design with extensive experience in breast-imaging software. For more information, visit . HALO Media Contact: Capwell Communications media@capwellcomm.com 949-999-3303 Ikonopedia Media Contact: Emily.Crane@ikonopedia.com 801-673-4272 References 1. Childers CP, et al. National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer. J Clin Oncol. 2017 Dec 1;35(34):3800-3806. PMC5707208. 2. Riedl CC, et al. Triple-Modality Screening Trial for Familial Breast Cancer Underlines the Importance of Magnetic Resonance Imaging and Questions the Role of Mammography and Ultrasound Regardless of Patient Mutation Status, Age, and Breast Density. Journal of Clinical Oncology. 2015;33(10):1128-35. PMC5526626. 3. Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, Price K, Johansen Taber K. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Cancer. 2020;126(3):549–58. 4. Bae MS, Sung JS, Bernard-Davila B, Sutton EJ, Comstock CE, Morris EA. Survival Outcomes of Screening with Breast MRI in Women at Elevated Risk of Breast Cancer. J Breast Imaging. 2020 Feb;2(1):29-35. doi: 10.1093/jbi/wbz083. Epub 2020 Jan 15. PMID: 32055796; PMCID: PMC6999769. 5. Farhad Islami, MD, PhD, Elizabeth M Ward, PhD, Hyuna Sung, PhD, Kathleen A Cronin, PhD, Florence K L Tangka, PhD, Recinda L Sherman, PhD, Jingxuan Zhao, MPH, Robert N Anderson, PhD, S Jane Henley, MSPH, K Robin Yabroff, PhD, Ahmedin Jemal, DVM, PhD, Vicki B Benard, PhD, Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics, JNCI: Journal of the National Cancer Institute, Volume 113, Issue 12, December 2021, Pages 1648–1669,

SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the value of genetic insights to guide and clarify cancer treatment and risk assessment. The presentations underscore Myriad’s commitment to partnering with oncologists and other healthcare partners to support health equity and provide data-driven insights to help guide clinical care and improve outcomes. They follow the recent launch of Precise™ Oncology Solutions, a comprehensive suite of solutions offering germline testing, tumor profiling, and companion diagnostic options, including evaluation for homologous recombination deficiency (HRD). The suite offers a streamlined testing experience designed to help oncologists recommend personalized treatment plans for their patients. Precise Oncology Solutions currently includes Myriad’s Precise™ Tumor Test, MyRisk™ Hereditary Cancer Test and its two FDA-approved companion diagnostic tests: MyChoice® CDx and BRACAnalysis CDx®. A new Precise Treatment Registry combines germline, somatic and HRD genetic data to accelerate the pace of precision cancer research and equitable advancements in patient care. Additionally, Myriad recently announced it will expand its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to offer a liquid biopsy therapy selection test as part of its growing oncology portfolio in 2023. Also at ASCO, Myriad will highlight a validation study for its market-leading MyRisk Hereditary Cancer Test with RiskScore®, the first polygenic breast cancer risk assessment clinically and analytically validated for women of all ancestries. Providers can gain critical insights to help identify women with an increased risk of breast cancer who do not have a harmful mutation in well-known breast cancer genes, like BRCA1. “Cancer prevention and treatment are most effective when informed by genetic insights,” said Thomas Slavin, M.D., chief medical officer, Myriad Genetics. “Our recent portfolio expansion and presentations at ASCO highlight our efforts to continually grow and innovate to better support physicians with comprehensive data-driven answers that inform treatment decisions, reduce healthcare disparities, and improve outcomes for all patients.” Data from Myriad to be presented at the meeting: A breast cancer (BC) risk model incorporating Tyrer-Cuzick version 8 (TCv8) and a polygenic risk score for diverse ancestries (Abstract #366104) Session Type: Poster SessionDate: Monday, June 6, 2022Time: 8:00-11:00 a.m. CDT This is the first breast cancer risk model to include breast density, family history and a polygenic risk score (PRS) based on genetically determined ancestry that is validated for diverse populations. The addition of PRS substantially improved risk stratification over TCv8 alone and may allow for a more personalized approach to breast cancer risk reduction. Ancestry-specific risk of triple-negative breast cancer (TNBC) associated with germline pathogenic variants (PV) in hereditary cancer (CA) predisposition genes (Abstract #377784) Session Type: Poster Discussion Date: Monday, June 6, 2022Time: 4:30-6:00 p.m.; 1:15-4:15 p.m. CDT In this population of women who had multigene panel testing, pathogenic variants in BRCA1, BRCA2, PALB2, RAD51C, RAD51D, and BARD1 were associated with substantial risk of triple-negative breast cancer (TNBC). There were no significant differences in pathogenic variant associated TNBC risks across ancestries. TNBC was reported more frequently in women of African ancestry. Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer (Abstract #364894)Session Type: Poster SessionDate: Monday, June 6, 2022Time: 8:00-11:00 a.m. CDT This exploratory analysis evaluated the ability of ≥ 33 or ≥ 42 genomic instability score (GIS) thresholds to predict response to platinum-based treatment in patients with triple-negative breast cancer. This study of 204 tumors of mixed BRCA wild-type, BRCA mutations and unknown showed that a GIS of ≥ 33 may be the most appropriate threshold to predict response to platinum-based treatment in patients with TNBC; however, a prospective trial is needed. Adherence to EndoPredict test scores for extended endocrine therapy management in the prospective EndoPredict Extended Endocrine Trial (EXET) (Abstract #371368)Session Type: Poster SessionDate: Monday, June 6, 2022Time: 8:00 -11:00 a.m. CDT In this cohort of patients, even when accounting for other clinical factors such as node status, tumor grade, age at diagnosis, and other variables, Myriad’s EndoPredict® Breast Cancer Prognostic Test provided significant information for clinical decisions on extended endocrine therapy. About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and commercializes genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com. Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved. Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company presenting multiple studies at the 2022 ASCO Annual Meeting, the company’s expansion of its strategic partnership with Intermountain Precision Genomics to offer a liquid biopsy therapy selection test in 2023, the company’s plan to highlight a validation study for its MyRisk Hereditary Cancer Test with RiskScore at the 2022 ASCO Annual Meeting, and the company’s strategic imperatives under the caption “About Myriad Genetics.” These “forward-looking statements” are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on the company’s operations and the demand for its products and services and the company’s ability to efficiently and flexibly manage its business; the risk that sales and profit margins of the company’s existing molecular diagnostic tests may decline or that the company may not be able to operate its business on a profitable basis; risks related to the company’s ability to generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests; risks related to changes in governmental or private insurers’ coverage and reimbursement levels for the company’s tests or the company’s ability to obtain reimbursement for its new tests at comparable levels to its existing tests; risks related to increased competition and the development of new competing tests and services; the risk that the company may be unable to develop or achieve commercial success for additional molecular diagnostic tests in a timely manner, or at all; the risk that the company may not successfully develop new markets for its molecular diagnostic tests, including the company’s ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying the company’s molecular diagnostic tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating and constructing the company’s laboratory testing facilities; risks related to public concern over genetic testing in general or the company’s tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to the company’s ability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all; risks related to the company’s ability to successfully integrate and derive benefits from any technologies or businesses that it licenses, acquires, or develops; risks related to the company’s projections about the potential market opportunity for the company’s current and future products; the risk that the company or its licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying the company’s tests; the risk of patent-infringement claims or challenges to the validity of the company’s patents; risks related to changes in intellectual property laws covering the company’s molecular diagnostic tests, or patents or enforcement, in the United States and foreign countries; risks related to security breaches, loss of data and other disruptions, including from cyberattacks; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that the company may be unable to comply with financial operating covenants under the company’s credit or lending agreements; risks related to the material weakness related to general information technology controls, including the impact thereof and the company’s remediation plan, and its ability to achieve and maintain effective disclosure controls and procedures and internal control over financial reporting; risks related to current and future lawsuits, including product or professional liability claims; and other factors discussed under the heading “Risk Factors” contained in Item 1A of the company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on February 25, 2022, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Media Contact:Investor Contact:Megan ManzariNathan Smith(385) 318-3718(801) 505-5067Megan.Manzari@myriad.com Nathan.Smith@myriad.com